Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

03.04.2020 | original article | Ausgabe 1-2/2021 Open Access

Wiener klinische Wochenschrift 1-2/2021

Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children

Results of a prospective study on behalf of the German-Austrian-Swiss GVHD Consortium

Wiener klinische Wochenschrift > Ausgabe 1-2/2021
MD Anita Lawitschka, Matthias Brunmair, Dorothea Bauer, Natalia Zubarovskaya, Rosemarie Felder-Puig, Brigitte Strahm, Peter Bader, Gabriele Strauss, Michael Albert, Irene von Luettichau, Hildegard Greinix, Daniel Wolff, Christina Peters
Wichtige Hinweise
The original online version of this article was revised: Due to a breach of copyright.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s00508-021-01902-2.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



The psychometric properties of an instrument, the Activity Scale for Kids-performance (ASKp), were assessed which was proposed to capture physical functioning after allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, this multicenter observational prospective study investigated the influence of clinical correlates focusing on chronic graft-versus-host disease (cGVHD).


Patient-reported ASKp, clinician-reported Karnofsky/Lansky status (KPS/PSS), patient characteristics and cGVHD details were assessed of 55 patients with a median age of 12 years at baseline after day +100 post-HSCT and every 3 months during the next 18 months. The psychometric properties were evaluated and ASKp and KPS/PSS status was compared using ANOVAS and multiple regression models.


The German version of the ASKp showed good psychometric properties except for ceiling effects. Discrimination ability of the ASKp was good regarding the need for devices but failed to predict cGVHD patients. Both the ASKp and the KPS/PSS were associated with patients after adoptive cell therapy being in need for devices, suffering from overlap cGVHD and from steroid side effects but not with patients’ age and gender. In contrast to the KPS/PSS the ASKp only showed significant differences after merging moderate and severe cGHVD patients when comparing them to No-cGVHD (F = 4.050; p = 0.049), being outperformed by the KPS/PSS (F = 20.082; p < 0.001).


The ASKp showed no clear advantages compared to KPS/PSS even though economical and patients’ effort was higher. Further application range may be limited through ceiling effects. Both should be taken into consideration. Therefore, the results may not support the usage of ASKp after HSCT and rather suggest KPS/PSS, both patient and clinician reported.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2021

Wiener klinische Wochenschrift 1-2/2021 Zur Ausgabe

mitteilungen der gesellschaft

mitteilungen der gesellschaft